ASX Release

CLINICAL TRIAL OF ArTiMist™ MALARIA TREATMENT IN CHILDREN

STATUS REPORT

Eastland Medical Systems Ltd (ASX:EMS) announces today that it has received advice from Mr. Calvin Ross (R&D Director of ProtoPharma Ltd) following his recent final visit to Rwanda to review progress of the clinical trial. He reports:

- The trial has been successfully completed with 30 patients being treated; 15 with ArTiMist™ spay and 15 with intravenous Quinine.
- Completion has been achieved well within time due to recruitment being well organised by the clinical trial site staff in Rwanda.
- The clinicians found ArTiMist™ very easy to use and more convenient for the patients compared to an intravenous delivery set up by the bed.

The next stage is a full analysis of all collected data including analysis of the blood samples sent to Malaysia for a full bio-analytical profile of ArTiMist™ in treated patients.

A significant number of scientists are now working on preparing a full report which will then be audited and signed off by independent experts prior to release.

The audit complies with requirements set out under the International Conference on Harmonisation (ICH) Guidelines.

ProtoPharma has further reported:

- the final audited report is expected to be issued by the end of April 2010.

Highlights

- **Phase 1 multi-dose clinical trials for ArTiMist™ were undertaken in South Africa in February 2008 with positive results indicating the formulation was well tolerated and showed no adverse effects in any of the trial subjects.**
- **Clinical Field Trial completed in February 2010 in Rwanda.**

54 Lindsay St Perth, Western Australia, 6000
PO Box 8027, Perth Business Centre, WA, 6849
T: +61 8 9436 9500 F: +61 8 9436 9505
E: d.patterson@eastlandmedical.com.au

ASX Release

Highlights

On receipt of that final report, and subject to its findings and recommendations, Eastland will:

- establish with ProtoPharma what further confirmatory, registration-focused clinical work is required, in advance of seeking an interim regulatory license from the host country.
- be in a position to engage in preliminary discussions with the following organisations:
  - W.H.O regarding their Pre-Qualification Programme for Essential Medicines.
  - Medicines for Malaria Venture (MMV).
  - Drugs for Neglected Diseases initiative (DNDi).
- elevate its level of engagement with select international pharmaceutical companies that have expertise in tropical diseases and an established foot-print within both the developing countries of Africa and the markets of India, Asia and the Pacific.
- mandate an Australian corporate consulting group with specific pharmaceutical expertise to advise on establishing a strategic alliance to assist with further project development and commercialisation.

Further information:
Dermot Patterson
CEO and Company Secretary
Eastland Medical Systems Ltd
t: +61 8 9436 9500
www.eastlandmedical.com.au

54 Lindsay St Perth, Western Australia, 6000
PO Box 8027, Perth Business Centre, WA, 6849
T: +61 8 9436 9500 F: +61 8 9436 9505
E: d.patterson@eastlandmedical.com.au